Wani Shariq Ahmad, Qudrat Salma, Zubair Hina, Iqbal Zahra, Gulzar Babar, Aziz Sundal, Inayat Arsalan, Safi Danish, Kamran Amir
Department of Internal Medicine, Government medical college, Srinagar, India.
internal Medicine, Khyber teaching hospital, Peshawar, Pakistan.
J Oncol Pharm Pract. 2025 Jan;31(1):119-127. doi: 10.1177/10781552241275943. Epub 2024 Aug 22.
To study the role of Osteoclast inhibitors in advanced prostate cancer metastasis treatment and their efficacy in reducing skeletal related events.
DATA SOURCE: A comprehensive search was done using search terms as "osteoclast inhibitors" "Bisphosphonates" "Zoledronic acid" " pamidronate" " Alendronate" "Denosumab" " Prostate cancer metastasis" in pubmed and Google scholar. Relevant articles were screened and collected . The collected articles were used to frame the review and data showing use of Osteoclast inhibitors In prostate cancer bone metastasis was collected.
Prostate cancer metastasizes most commonly to the skeleton thus leading to significant morbidity ranging from pain, pathological fractures to spinal cord compression and are the primary cause of patient disability and reduced quality of life.Initially, radiation therapy and radiopharmaceuticals were the mainstay of treatment however the role of Bisphosphonates and denosumab has become an integral part of therapy to manage metastatic prostate cancer. These agents significantly decrease skeletal related events and enhance patients quality of life. Emerging therapies like Radium-223 have also shown promise in reducing skeletal related events and also improving survival rates in patients with bone metastasis. Other treatment options which are being used are systemic agents like Docetaxel, cabazitaxel, hormonal therapies like abiraterone and enzalutamide. Immunotherapy with sipuleucel-T has demonstrated a reduction in mortality among prostate cancer patients with metastasis, highlighting the need for further research in this area. Ongoing studies are investigating novel agents that target both tumor cells and the bone microenvironment.
Osteoclast inhibitors are effective in reducing skeletal related events in advanced bone metastasis and improve the quality of life of patients.
研究破骨细胞抑制剂在晚期前列腺癌转移治疗中的作用及其在减少骨相关事件方面的疗效。
数据来源：在PubMed和谷歌学术上使用“破骨细胞抑制剂”“双膦酸盐”“唑来膦酸”“帕米膦酸”“阿仑膦酸钠”“地诺单抗”“前列腺癌转移”等检索词进行全面搜索。筛选并收集相关文章。收集的文章用于构建综述，并收集显示破骨细胞抑制剂在前列腺癌骨转移中应用的数据。
前列腺癌最常转移至骨骼，从而导致从疼痛、病理性骨折到脊髓压迫等显著的发病率，是患者残疾和生活质量下降的主要原因。最初，放射治疗和放射性药物是主要治疗方法，然而双膦酸盐和地诺单抗的作用已成为治疗转移性前列腺癌不可或缺的一部分。这些药物显著减少骨相关事件并提高患者生活质量。像镭-223这样的新兴疗法在减少骨相关事件以及提高骨转移患者生存率方面也显示出前景。正在使用的其他治疗选择包括多西他赛、卡巴他赛等全身用药，阿比特龙和恩杂鲁胺等激素疗法。西妥昔单抗免疫疗法已证明可降低转移性前列腺癌患者的死亡率，凸显了该领域进一步研究的必要性。正在进行的研究正在调查靶向肿瘤细胞和骨微环境的新型药物。
破骨细胞抑制剂在减少晚期骨转移中的骨相关事件方面有效，并改善患者生活质量。
